Holen Sie sich die Stockscreener-App
68.72
0.59%
0.40
Handel nachbörslich:
68.50
-0.22
-0.32%
Schlusskurs vom Vortag:
$68.32
Offen:
$68.96
24-Stunden-Volumen:
2.59M
Relative Volume:
1.62
Marktkapitalisierung:
$8.15B
Einnahmen:
$1.40B
Nettoeinkommen (Verlust:
$316.89M
KGV:
27.58
EPS:
2.4918
Netto-Cashflow:
$644.59M
1W Leistung:
-0.01%
1M Leistung:
+5.14%
6M Leistung:
-5.42%
1J Leistung:
+26.00%
1-Tages-Spanne:
$68.43
$69.55
1-Wochen-Bereich:
$67.50
$69.74
52-Wochen-Spanne:
$51.06
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
68.72 | 8.10B | 1.40B | 316.89M | 644.59M | 2.4918 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Implied Volatility Surging for Halozyme Therapeutics Stock Options - TradingView
Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a Promising 22.8% Potential Upside - DirectorsTalk Interviews
(HALO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Flat Share Price And Strong Longer Term Returns - Sahm
Halozyme Therapeutics Q1 earnings call highlights - MSN
HALO News | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme posts strong Q1 earnings, boosts share buyback with $1B program amid robust royalty growth - Pluang
Halozyme Therapeutics: Royalty King (NASDAQ:HALO) - Seeking Alpha
New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO) - simplywall.st
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Alteogen Gains Momentum in Patent Defense for Merck's Subcutaneous Keytruda - thelec.net
Halozyme Therapeutics (HALO) Stock Analysis: A 27.3% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - MSN
Halozyme Therapeutics Experiences Valuation Adjustment Amid Competitive Biotechnology Landscape - Markets Mojo
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Halozyme Therapeutics Q1 2026 Earnings Review | HALO StockNews and Statistics - IndexBox
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO) - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook - Yahoo Finance
Morgan Stanley Smith Barney files Form 144 (NASDAQ: HALO) to sell 14,700 shares - Stock Titan
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback - Sahm
Arbejdsmarkedets Tillaegspension Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback - MSN
Halozyme appoints Darren Snellgrove as CFO - MSN
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75 - Moomoo
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative - Sahm
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares - MarketBeat
Halozyme CEO Helen Torley sells $3.43m in stock By Investing.com - Investing.com Nigeria
Halozyme CEO Helen Torley sells $3.43m in stock - Investing.com
Halozyme (HALO) CEO Torley exercises 50K options and sells 50K shares under 10b5-1 plan - Stock Titan
(HALO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Halozyme Therapeutics Earnings: What To Look For From HALO - Yahoo Finance
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK - Insider Monkey
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41 - Moomoo
HALO Stock Jumps After Earnings Beat And $1B Buyback - StocksToTrade
Halozyme jumps as Q1 results, $1B buyback authorization, and new partnership updates lift sentiment - Quiver Quantitative
Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00 - MarketBeat
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley - marketscreener.com
Halozyme Therapeutics Shares Jumping 8.1% on Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and … - AlphaStreet
Halozyme Therapeutics (NASDAQ:HALO) Trading Up 6.6% Following Strong Earnings - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript - Insider Monkey
Citizens reiterates Halozyme stock rating on strong Q1 results By Investing.com - Investing.com Nigeria
Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating - marketscreener.com
Citizens reiterates Halozyme stock rating on strong Q1 results - Investing.com
Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlight - GuruFocus
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96 - Moomoo
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Halozyme Therapeutics Inc-Aktie (HALO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
May 11 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
May 12 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
May 13 '26 |
Option Exercise |
12.07 |
10,000 |
120,700 |
777,780 |
| Torley Helen | PRESIDENT AND CEO |
May 12 '26 |
Sale |
71.75 |
20,000 |
1,435,027 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
May 11 '26 |
Sale |
65.35 |
20,000 |
1,306,940 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
May 13 '26 |
Sale |
69.19 |
10,000 |
691,908 |
767,780 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):